|Day Low/High||2.40 / 2.45|
|52 Wk Low/High||1.22 / 4.28|
Data from an interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented
Seasoned executive with over two decades of corporate finance and operational leadership experience in the biopharmaceuticals industry to join Cellectar team
Independent Data Monitoring Committee recommends the study continue to higher dose after first dose deemed safe and tolerated
Covers composition of matter and method of use for proprietary PDCs™ in combination with anti-cancer agents
Conference call to be held tomorrow at 8:30 a.m. Eastern time
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.